MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Funding Opportunities: Pioneers, Architects & Consolidators
Funding: U.S. Federal
*Funding: HHS
*HHS: Contracts, Contractors & Awards
*BARDA: Contracts (IDIQ, GWACS, Etc.), Contractors & Awardees
*Contractors & Awardees: BARDA
Achaogen (NASDAQ:AKAO)
Organization & Developments: Archaogen
Parents
Achaogen (NASDAQ:AKAO)
Children
2010: Achaogen wins $64M biodefense contract
2017: Achaogen nabs $18M BARDA contract to support C-Scape development; shares up 2% premarket - Achaogen (NASDAQ:AKAO)
2017: Achaogen: Rebound Likely In 2018 - Achaogen (NASDAQ:AKAO)
2018: A Wild Week For Achaogen_seekingalpha.com
2018: Achaogen: Explicating The Prospects Of C-Scape - Achaogen (NASDAQ:AKAO)
2018: Achaogen: Falling Knife Or Major Bargain?_seekingalpha.com
2018: Achaogen: Not Too Late To Catch The Rally - Achaogen (NASDAQ:AKAO)
2018: Floundering in the wake of an FDA approval, Achaogen makes a second round of deep cuts to stay alive – Endpoints News
2018: It's a good news, bad news FDA approval for Achaogen's powerful antibiotic Zemdri
2019: Achaogen Eyes Sale in Bankruptcy Auction a Year After FDA Approval_xconomy.com
BARDA is supporting the drug's development for biological threats, including Yersinia pestis, which causes bubonic plague, and Francisella tularensis, which causes tularemia.
Therapeutics for combating the increasing bacterial resistance to antibiotics
Jumps
*Key People: Archaogen
Finance & Acquisitions: Archaogen